<div id=toc></div>

# Table of Contents

- [q-bio.QM](#q-bio.QM) [Total: 3]
- [cs.AI](#cs.AI) [Total: 1]
- [eess.IV](#eess.IV) [Total: 1]


<div id='q-bio.QM'></div>

# q-bio.QM [[Back]](#toc)

### [1] [Drug discovery guided by maximum drug likeness](https://arxiv.org/abs/2512.21895)
*Hao-Yu Zhu,Shi-Jie Du,Lu Xu,Wei Shi*

Main category: q-bio.QM

TL;DR: 提出最大药物相似性概念和五重MDL策略，通过33个深度学习子模型构建33维属性谱，从1600万分子库中筛选出15个高潜力分子，实验验证M2化合物具有强抗菌活性和优于头孢呋辛的结合稳定性。


<details>
  <summary>Details</summary>
Motivation: 药物发现领域存在高淘汰率和临床转化率低的问题，需要新的筛选范式来克服支架限制，发现具有良好前景的抗耐药菌先导化合物。

Method: 开发五重MDL策略，集成33个深度学习子模型构建33维属性谱，从五个维度（理化性质、药代动力学、疗效、安全性、稳定性）量化候选分子与临床批准药物的全局表型对齐，使用药物相似性评分从1600万分子库中优先筛选。

Result: 筛选出15个高潜力分子，其中先导化合物M2表现出强抗菌活性（MIC为25.6 ug/mL），结合稳定性优于头孢呋辛（MM-PBSA计算为-38.54 kcal/mol，RMSD为2.8 Å）。

Conclusion: 5F-MDL策略能够克服支架限制，为发现具有良好前景的抗耐药菌先导化合物提供高效途径，有望改善药物发现的高淘汰率和临床转化问题。

Abstract: To overcome the high attrition rate and limited clinical translatability in drug discovery, we introduce the concept of Maximum Drug-Likeness (MDL) and develop an applicable Fivefold MDL strategy (5F-MDL) to reshape the screening paradigm. The 5F-MDL strategy integrates an ensemble of 33 deep learning sub-models to construct a 33-dimensional property spectrum that quantifies the global phenotypic alignment of candidate molecules with clinically approved drugs along five axes: physicochemical properties, pharmacokinetics, efficacy, safety, and stability. Using drug-likeness scores derived from this 33-dimensional profile, we prioritized 15 high-potential molecules from a 16-million-molecule library. Experimental validation demonstrated that the lead compound M2 not only exhibits potent antibacterial activity, with a minimum inhibitory concentration (MIC) of 25.6 ug/mL, but also achieves binding stability superior to cefuroxime, as indicated by Molecular Mechanics Poisson-Boltzmann surface area (MM-PBSA) calculations of -38.54 kcal/mol and a root-mean-square deviation (RMSD) of 2.8 A. This strategy could overcome scaffold constraints and offers an efficient route for discovering lead compounds with favorable prospects against drug-resistant bacteria.

</details>


### [2] [Characterizing Fungal Infections in the All of Us Research Program](https://arxiv.org/abs/2512.21952)
*Md Fantacher Islam,Emeral Norzagaray,Corneliu Antonescu,Vignesh Subbian*

Main category: q-bio.QM

TL;DR: 利用All of Us研究项目数据构建三种真菌感染队列，分析流行病学特征并评估临床数据质量，发现数据集有价值但存在专业生物标志物数据质量问题


<details>
  <summary>Details</summary>
Motivation: 真菌感染在美国日益成为公共卫生问题，但传统监测方法常低估其实际负担，需要利用大规模研究项目数据更好地表征这些感染并评估相关数据质量

Method: 从All of Us研究项目的40多万参与者中，利用电子健康记录数据构建了三个真菌感染队列（球孢子菌病1,173例、曲霉病687例、组织胞浆菌病345例），分析地理和社会人口学分布，并对10个关键实验室生物标志物进行数据质量评估，包括数据完整性、单位一致性和测量一致性

Result: 分析确认了已知的流行病学模式：球孢子菌病集中在西南部，组织胞浆菌病在中西部；感染主要影响老年人、男性和非西班牙裔白人。数据质量评估显示一般血液学标志物完整性高（如血红蛋白>70%），但专业生物标志物可用性有限（如β-1,3-葡聚糖<15%）；测量一致性强但关键炎症标志物的单位一致性差

Conclusion: All of Us数据集是表征真菌感染的宝贵资源，但专业生物标志物在完整性和一致性方面存在显著数据质量问题，需要解决这些问题以增强其在稳健临床研究中的适用性

Abstract: Fungal infections, such as Coccidioidomycosis, Aspergillosis, and Histoplasmosis, represent a growing public health concern in the United States. The rising incidence of these mycoses is linked to climate shifts, demographic changes, and social determinants of health. However, the actual burden of these infections is often underestimated by traditional surveillance methods. Therefore, this study aims to characterize these infections within the All of Us Research Program and evaluate the quality of clinical and health data related to fungal infections. We constructed three fungi cohorts of Coccidioidomycosis (n=1,173), Aspergillosis (n=687), and Histoplasmosis (n=345) among over 400,000 participants using electronic health record data. We analyzed geographic and sociodemographic distributions and performed a data quality assessment on ten key laboratory biomarkers to evaluate data completeness, unit conformance, and measurement concordance within a 90-day window of diagnosis. Our analysis confirmed known epidemiological patterns, including the geographic distributions of Coccidioidomycosis in the Southwest and Histoplasmosis in the Midwest. Fungal infections disproportionately affected older adults, males, and White non-Hispanic individuals. The data quality assessment revealed high completeness for general hematology markers (e.g., Hemoglobin > 70%) but limited availability for biomarkers, such as Beta 1,3 Glucan (< 15%). While measurement concordance was strong (e.g., hemoglobin-hematocrit correlation, r = 0.94), unit conformance was poor for key inflammatory markers, such as erythrocyte sedimentation rate. In conclusion, the All of Us dataset is a valuable resource for characterizing fungal infections. However, significant data quality issues related to completeness and conformance for specialized biomarkers must be addressed to enhance their applicability for robust clinical research.

</details>


### [3] [Sample volume as a key design parameter in affinity-based biosensors](https://arxiv.org/abs/2512.21997)
*Daan Beijersbergen,Jérôme Charmet*

Main category: q-bio.QM

TL;DR: 开发了一个考虑有限样本体积的生物传感器数学模型，能快速预测关键性能指标并优化设计，计算速度比商业软件快万倍以上。


<details>
  <summary>Details</summary>
Motivation: 生物传感器设计中样本体积这一关键参数被忽视，而传感器性能取决于目标分子的绝对数量而非仅浓度，这在样本有限时尤为重要。

Method: 建立了一个可处理的双室数学模型，整合了简化质量传输、Langmuir结合动力学和质量守恒，考虑了有限体积约束。

Result: 模型能准确预测检测时间和最小所需样本体积，计算速度比商业仿真软件快10,000倍以上，并通过实验验证了优化框架。

Conclusion: 该模型为生物传感器设计提供了定量优化规则，特别适用于即时检测和资源受限环境，已作为开源软件发布。

Abstract: Affinity-based biosensors have become indispensable in modern diagnostics and health monitoring. While considerable research has focused on optimizing analyte transport and binding kinetics, a fundamental parameter - sample volume - remains largely underexplored in biosensor design. This is critical because biosensor performance depends on the absolute number of target molecules present, not solely their concentration, making volume a key consideration where sample availability is limited. To address this gap, we developed a tractable two-compartment mathematical model integrating simplified mass transport, Langmuir binding kinetics, and mass conservation under finite volume constraints. Validated against experimental measurements and numerical simulations, the model accurately predicts critical performance metrics including assay time and minimum required sample volume while achieving more than a 10,000-fold reduction in computational time compared to commercial simulation packages. Through systematic analysis, we derived quantitative design rules for biosensor optimization that explicitly account for measurement time and sample volume as primary decision variables. We validated this framework experimentally by optimizing flow rate parameters for a quartz crystal microbalance (QCM) biosensor and retrospectively applied it to enhance sensitivity of published biosensor designs. Released as open-source software, our model enables researchers to gain mechanistic insights, optimize device performance, and make informed design decisions tailored to specific healthcare contexts, including point-of-care testing and resource-constrained environments.

</details>


<div id='cs.AI'></div>

# cs.AI [[Back]](#toc)

### [4] [Democratizing Drug Discovery with an Orchestrated, Knowledge-Driven Multi-Agent Team for User-Guided Therapeutic Design](https://arxiv.org/abs/2512.21623)
*Takahide Suzuki,Kazuki Nakanishi,Takashi Fujiwara,Hideyuki Shimizu*

Main category: cs.AI

TL;DR: OrchestRA是一个人类在环的多智能体平台，将生物学、化学和药理学统一为自主发现引擎，通过自主执行模拟和推理结果驱动迭代优化，将药物发现从随机搜索转变为可编程的循证工程学科。


<details>
  <summary>Details</summary>
Motivation: 当前治疗发现面临专业领域碎片化以及计算设计与生理验证之间的执行差距等挑战。虽然生成式AI有潜力，但现有模型通常只是被动助手而非自主执行者。

Method: OrchestRA采用人类在环的多智能体架构：1) Orchestrator协调整个流程；2) Biologist Agent基于大规模知识图谱（>1000万关联）进行深度推理识别高置信度靶点；3) Chemist Agent自主检测结构口袋进行从头设计或药物重定位；4) Pharmacologist Agent通过基于生理的药代动力学(PBPK)模拟评估候选药物。建立动态反馈循环，药代动力学和毒性特征直接触发结构再优化。

Result: 该平台将自主执行与人类指导无缝集成，使治疗设计民主化，将药物发现从随机搜索转变为可编程的循证工程学科。

Conclusion: OrchestRA通过统一生物学、化学和药理学领域，建立自主发现引擎，解决了治疗发现中的碎片化和执行差距问题，实现了从被动助手到主动执行者的转变。

Abstract: Therapeutic discovery remains a formidable challenge, impeded by the fragmentation of specialized domains and the execution gap between computational design and physiological validation. Although generative AI offers promise, current models often function as passive assistants rather than as autonomous executors. Here, we introduce OrchestRA, a human-in-the-loop multi-agent platform that unifies biology, chemistry, and pharmacology into an autonomous discovery engine. Unlike static code generators, our agents actively execute simulations and reason the results to drive iterative optimization. Governed by an Orchestrator, a Biologist Agent leverages deep reasoning over a massive knowledge graph (>10 million associations) to pinpoint high-confidence targets; a Chemist Agent autonomously detects structural pockets for de novo design or drug repositioning; and a Pharmacologist Agent evaluates candidates via rigorous physiologically based pharmacokinetic (PBPK) simulations. This architecture establishes a dynamic feedback loop where pharmacokinetic and toxicity profiles directly trigger structural reoptimization. By seamlessly integrating autonomous execution with human guidance, OrchestRA democratizes therapeutic design, transforming drug discovery from a stochastic search to a programmable evidence-based engineering discipline.

</details>


<div id='eess.IV'></div>

# eess.IV [[Back]](#toc)

### [5] [The Color-Clinical Decoupling: Why Perceptual Calibration Fails Clinical Biomarkers in Smartphone Dermatology](https://arxiv.org/abs/2512.21988)
*Sungwoo Kang*

Main category: eess.IV

TL;DR: 颜色校准虽能减少色差，但无法保证临床生物标志物的可靠性，存在"颜色-临床解耦"现象


<details>
  <summary>Details</summary>
Motivation: 研究智能手机远程皮肤病学中颜色校准对临床可靠性的影响，特别是在肤色较深的皮肤类型中

Method: 使用43,425张来自965名韩国受试者的图像，比较DSLR、平板和智能手机设备，分析线性颜色校正矩阵(CCM)标准化效果

Result: 颜色误差减少67-77%，但个体类型角(ITA)的设备间一致性差(ICC=0.40)，而黑色素指数一致性较好(ICC=0.77)，面部区域占颜色变异的25.2%

Conclusion: 当前颜色校准标准不足以支持临床级生物标志物提取，需要区域感知协议

Abstract: Smartphone-based tele-dermatology assumes that colorimetric calibration ensures clinical reliability, yet this remains untested for underrepresented skin phototypes. We investigated whether standard calibration translates to reliable clinical biomarkers using 43,425 images from 965 Korean subjects (Fitzpatrick III-IV) across DSLR, tablet, and smartphone devices. While Linear Color Correction Matrix (CCM) normalization reduced color error by 67-77% -- achieving near-clinical accuracy (Delta E < 2.3) -- this success did not translate to biomarker reliability.
  We identify a phenomenon termed "color-clinical decoupling": despite perceptual accuracy, the Individual Typology Angle (ITA) showed poor inter-device agreement (ICC = 0.40), while the Melanin Index achieved good agreement (ICC = 0.77). This decoupling is driven by the ITA formula's sensitivity to b* channel noise and is further compounded by anatomical variance. Facial region accounts for 25.2% of color variance -- 3.6x greater than device effects (7.0%) -- challenging the efficacy of single-patch calibration. Our results demonstrate that current colorimetric standards are insufficient for clinical-grade biomarker extraction, necessitating region-aware protocols for mobile dermatology.

</details>
